Review Article

The Association between MUC5B Rs35705950 and Risks of Idiopathic Interstitial Pneumonia, Systemic Sclerosis Interstitial Lung Disease, and Familial Interstitial Pneumonia: A Meta-Analysis


Background: Interstitial lung disease (ILD) is a category of chronic lung diseases with more than 200 subtypes. Idiopathic interstitial pneumonia (IIP), systemic sclerosis (SSc) ILD, and familial interstitial pneumonia (FIP) are three major groups of lung diseases with different causes or with unknown causes. Mucin5B (MUC5B) belongs to the mucin family, which contribute to the lubricating and viscoelastic properties of the whole saliva, normal lung mucus, and cervical mucus. The association between MUC5B rs35705950 and ILDs risks has been widely studied. However, the results were inconclusive and inconsistent.

Methods: In the present meta-analysis, the database PubMed, Embase, Cochrane Central Register of Controlled Trials, CNKI and Chinese Biomedical Literature Database were searched till Aug 20th, 2018. Overall 16 publications with 28 studies, 76345 cases and 18402 controls were included.

Results: The results indicated a significant increase of overall IIP risk for TT genotype and T allele of the rs35705950 in all genetic models (TT vs GG, OR=9.11; TT vs GT+TT, OR=5.80; GT+TT vs GG, OR=4.34; T vs G, OR=4.03. P<0.0001). Subgroup analysis by subtypes of IIP revealed higher risks of TT genotype and T allele for IPF and iNSIP (P<0.05). A significant increase of FIP risk was also found for the TT genotype and T allele of the rs35705950 (TT vs GG, OR=17.08; GT+TT vs GG, OR=6.02; T vs G, OR=1.64.P<0.05).

Conclusion: No significant relations existed between the rs35705950 and SSc-ILD risks. MUC5B rs35705950 might be a predictor for the susceptibility of IIP and FIP.

1. King TE (2005). Clinical advances in the di-agnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med, 172: 268-279.
2. Marsha A, Mouna M (2020). Interstitial lung disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
3. Travis WD, Costabel U, Hansell DM, et al (2013). An official American Thoracic So-ciety/European Respiratory Society statement: Update of the international multidisciplinary classification of the idio-pathic interstitial pneumonias. Am J Respir Crit Care Med, 188(6): 733-48.
4. Steen VD, Medsger TA (2007). Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis, 66 (7): 940-944.
5. Seibold MA, Wise AL, Speer MC, et al (2011). A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med, 364(16): 1503-12.
6. Borie R, Kannengiesser C, Crestani B (2012). Familial forms of nonspecific in-terstitial pneumonia/idiopathic pulmo-nary fibrosis: Clinical course and genetic background. Curr Opin Pulm Med, 18(5): 455-461.
7. Horimasu Y, Hattori N, Ishikawa N, et al (2013). MUC5B promoter polymorphism is significantly associated with idiopathic interstitial pneumonia in German but not in Japanese patients. Eur Respir J, 42 (Suppl 57) P2332.
8. Johnson C, Giles JT, Bathon J, Danoff SK (2013). Exploration Of The Muc5b Pol-ymorphism Frequency In Rheumatoid Arthritis Interstitial Lung Disease. Am J Respir Crit Care Med, 187: A5982.
9. Borie R, Crestani B, Dieude P, et al (2013). The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population. PLoS One,8(8): e70621.
10. Coghlan MA, Shifren A, Huang HJ, et al (2014). Sequencing of idiopathic pulmo-nary fibrosis-related genes reveals inde-pendent single gene associations. BMJ Open Respir Res, 1(1): e000057.
11. Fingerlin TE, Murphy E, Zhang W, et al (2013). Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet, 45(6): 613-20.
12. Helling BA, Gerber AN, Kadiyala V, et al (2017). Regulation of MUC5B Expres-sion in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol, 57(1): 91-99.
13. Horimasu Y, Ohshimo S, Bonella F, et al (2015). MUC5B promoter polymorphism in Japanese patients with idiopathic pul-monary fibrosis. Respirology, 20(3): 439-44.
14. Jiang H, Hu Y, Shang L, Li Y, Yang L, Chen Y (2015). Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fi-brosis. Int J Clin Exp Pathol, 8(11): 14953-8.
15. Kishore A, Žižková V, Kocourková L, et al (2016). Association study for 26 candi-date loci in idiopathic pulmonary fibrosis patients from four European popula-tions. Front Immunol, 7: 274.
16. Noth I, Zhang Y, Ma SF, et al (2013). Ge-netic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med, 1(4): 309-317.
17. Stock CJ, Sato H, Fonseca C, et al (2013). Mucin 5B promoter polymorphism is as-sociated with idiopathic pulmonary fibro-sis but not with development of lung fi-brosis in systemic sclerosis or sarcoido-sis. Thorax, 68(5): 436-41.
18. van der Vis JJ, Snetselaar R, Kazemier KM, et al (2016). Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology, 21(4): 712-7.
19. Wang CL, Zhuang Y, Guo WW, et al (2014). Mucin 5B Promoter Polymorphism Is Associated with Susceptibility to Intersti-tial Lung Diseases in Chinese Males. PLoS One,9(8): e104919.
20. Wei R, Li C, Zhang M, et al (2014). Associa-tion between MUC5B and TERT poly-morphisms and different interstitial lung disease phenotypes. Transl Res, 163(5): 494-502.
21. Zhang Y, Noth I, Garcia JG, et al (2011). A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med, 364(16): 1576-7.
22. Peljto AL, Steele MP, Fingerlin TE, et al (2012). The pulmonary fibrosis-associated MUC5B promoter polymor-phism does not influence the develop-ment of interstitial pneumonia in systemic sclerosis. Chest, 142(6): 1584-1588.
23. Johnson C, Rosen P, Lloyd T, et al (2017). Exploration of the MUC5B promoter variant and ILD risk in patients with au-toimmune myositis. Respir Med, 130: 52-54.
24. Marin F, Luquet G, Marie B, et al (2008). Molluscan shell proteins: primary struc-ture, origin, and evolution. Curr Top Dev Biol, 80: 209-76.
25. Johnson DC (2011). Airway mucus function and dysfunction. N Engl J Med, 364(10): 978.
26. Roy MG, Livraghi-Butrico A, Fletcher AA, et al (2014). Muc5b is required for airway defence. Nature, 505(7483): 412-6.
27. Dickey BF, Whitsett JA (2017). Understand-ing Interstitial Lung Disease: It's in the Mucus. Am J Respir Cell Mol Biol, 57(1): 12-14.
28. Goldin JG, Lynch DA, Strollo DC, et al (2008). High-resolution CT scan findings in patients with symptomatic scleroder-ma-related interstitial lung disease. Chest, 134(2): 358-367.
29. Dieudé P, Guedj M, Wipff J, et al (2009). Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmo-nary fibrosis. Arthritis Rheum, 60(1): 225-33.
IssueVol 49 No 12 (2020) QRcode
SectionReview Article(s)
Idiopathic interstitial pneumonia Familial interstitial pneumonia; Polymorphism Meta-analysis

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
LUO H-Q, HUANG C-X, LI G-Y, LI P, ZHANG S-M, LI H-G, HAN L, BAO M-H. The Association between MUC5B Rs35705950 and Risks of Idiopathic Interstitial Pneumonia, Systemic Sclerosis Interstitial Lung Disease, and Familial Interstitial Pneumonia: A Meta-Analysis. Iran J Public Health. 2020;49(12):2240-2250.